Cargando…
Making Sure That Orphan Incentives Tip the Right Way in Europe
The delicate balance of funding research and development of treatments for rare disease is only imperfectly achieved in Europe, and even the current provisional equilibrium is under a new threat from well-intentioned policy changes now in prospect that could—in addition to the intrinsic complexities...
Autores principales: | Horgan, Denis, Koeva-Balabanova, Jasmina, Capoluongo, Ettore, Jagielska, Beata, Cattaneo, Ivana, Kozaric, Marta, Tumiene, Birute, El Ahl, Jean-Paul, Lal, Jonathan A., Kalra, Dipak, Malats, Núria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498781/ https://www.ncbi.nlm.nih.gov/pubmed/36141212 http://dx.doi.org/10.3390/healthcare10091600 |
Ejemplares similares
-
The Three-Way Pendulum of Healthcare Innovation
por: Horgan, Denis, et al.
Publicado: (2017) -
Digitalisation and COVID-19: The Perfect Storm
por: Horgan, Denis, et al.
Publicado: (2020) -
Factors Affecting Citizen Trust and Public Engagement Relating to the Generation and Use of Real-World Evidence in Healthcare
por: Horgan, Denis, et al.
Publicado: (2022) -
Bringing Onco-Innovation to Europe’s Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine
por: Horgan, Denis, et al.
Publicado: (2021) -
Incentives for orphan drug research and development in the United States
por: Seoane-Vazquez, Enrique, et al.
Publicado: (2008)